2026 Volume 15 Issue 3
Creative Commons License

Explainable and Uncertainty-Aware QSAR for Pharmaceutical Decision Making


, , , ,
  1. Department of Explainable QSAR and Uncertainty, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
  2. Department of Pharmaceutical Decision Making, Faculty of Pharmacy, University of Ilorin, Ilorin, Nigeria.
  3. Department of Uncertainty-Aware Modeling, Faculty of Pharmaceutical Sciences, Federal University of Agriculture Abeokuta, Abeokuta, Nigeria.
  4. Department of Drug Discovery Informatics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan.
Abstract

Quantitative structure–activity relationship (QSAR) models increasingly support pharmaceutical prioritization, yet predictive accuracy alone does not establish whether a model is sufficiently interpretable or reliable for a specific decision. Explainability methods may identify molecular features associated with predictions, whereas uncertainty methods estimate confidence, calibration, or susceptibility to error; these functions are related but not interchangeable. A systematic review of literature published from 2017 to September 2026 was conducted across six web-accessible scholarly search and publication sources using combinations of QSAR, molecular-property prediction, ADMET, explainability, attribution, counterfactual explanation, uncertainty quantification, calibration, conformal prediction, chemical-space generalization, and pharmaceutical decision terms. The review flow comprised 1,311 identified records, 342 retained after title screening, 87 retained after abstract assessment, and 29 finally included studies. Evidence was classified according to prediction context, explanation target, uncertainty formulation, validation strategy, chemical-space boundary, and relationship to pharmaceutical decision making. The literature showed that explanation quality cannot be inferred from predictive accuracy and that explanation outputs can vary with representation, model architecture, structural attribution unit, and benchmark design. Uncertainty estimates likewise differed across model classes, data distributions, activity-cliff regions, and calibration procedures. Counterfactual and contrastive approaches offered chemically explicit interrogation of prediction boundaries, but predicted structural alternatives did not constitute experimental causal evidence. Few studies directly connected joint explainability–uncertainty assessment to prospective pharmaceutical decisions. QSAR outputs become more defensible for pharmaceutical decision making when prediction, explanation, uncertainty, validation, and transferability are treated as distinct evidentiary layers. The review therefore develops a decision-oriented synthesis in which explanations require independent fidelity testing and uncertainty requires calibration within the chemical and decision domain in which it is used.


How to cite this article
Vancouver
Bello A, Sule Z, Musa I, Adeyemi G, Youssef A. Explainable and Uncertainty-Aware QSAR for Pharmaceutical Decision Making. Int J Pharm Res Allied Sci. 2026;15(3):74-84. https://doi.org/10.51847/wgZwhbZLOq
APA
Bello, A., Sule, Z., Musa, I., Adeyemi, G., & Youssef, A. (2026). Explainable and Uncertainty-Aware QSAR for Pharmaceutical Decision Making. International Journal of Pharmaceutical Research and Allied Sciences, 15(3), 74-84. https://doi.org/10.51847/wgZwhbZLOq
Related articles:
Most viewed articles:
Issue 1 Volume 16 (2027)